within Pharmacolibrary.Drugs.ATC.J;

model J04AB05_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.69,
    Cl             = 6.833333333333332e-05,
    adminDuration  = 600,
    adminMass      = 900 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.092,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004833333333333333,
    Tlag           = 21.0,            
    Vdp             = 0.052,
    k12             = 10.6,
    k21             = 10.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AB05_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rifapentine is a long-acting rifamycin antibiotic used primarily in the treatment of tuberculosis (TB), including latent TB infection and active pulmonary TB. It acts by inhibiting DNA-dependent RNA polymerase in Mycobacterium tuberculosis. Rifapentine is approved by several regulatory agencies including the FDA and is commonly used in combination regimens with other anti-tuberculous agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in HIV-positive subjects with latent TB receiving weekly 900 mg oral dosing.</p><h4>References</h4><ol><li><p>MacDougall, C, et al., &amp; Louie, J (2022). Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. <i>Pharmacotherapy</i> 42(4) 343–361. DOI:<a href=\"https://doi.org/10.1002/phar.2672\">10.1002/phar.2672</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35152432/\">https://pubmed.ncbi.nlm.nih.gov/35152432</a></p></li><li><p>Marshall, JD, et al., &amp; Kearns, GL (1999). Rifapentine pharmacokinetics in adolescents. <i>The Pediatric infectious disease journal</i> 18(10) 882–888. DOI:<a href=\"https://doi.org/10.1097/00006454-199910000-00009\">10.1097/00006454-199910000-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10530584/\">https://pubmed.ncbi.nlm.nih.gov/10530584</a></p></li><li><p>Blake, MJ, et al., &amp; Kearns, GL (2006). Pharmacokinetics of rifapentine in children. <i>The Pediatric infectious disease journal</i> 25(5) 405–409. DOI:<a href=\"https://doi.org/10.1097/01.inf.0000214963.55217.9c\">10.1097/01.inf.0000214963.55217.9c</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16645503/\">https://pubmed.ncbi.nlm.nih.gov/16645503</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AB05_1;
